TGFB1 and melanoma: The blockade of the transforming growth factor-beta (TGF-β) pathway may be one of the most attractive strategies in malignant melanoma, providing a prospect of combination therapy with PD-1 inhibition through enhancing T cell activation and infiltration in tumors [10,11].